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Abstract
Background: Oncolytic viral tumor therapy is an emerging field in the fight against cancer with rising numbers of
clinical trials and the first clinically approved product (Adenovirus for the treatment of Head and Neck Cancer in
China) in this field. Yet, until recently no general (bio)marker or reporter gene was described that could be used to
evaluate successful tumor colonization and/or transgene expression in other biological therapies.
Methods: Here, a bacterial glucuronidase (GusA) encoded by biological therapeutics (e.g. oncolytic viruses) was
used as reporter system.
Results: Using fluorogenic probes that were specifically activated by glucuronidase we could show 1) preferential
activation in tumors, 2) renal excretion of the activated fluorescent compounds and 3) reproducible detection of
GusA in the serum of oncolytic vaccinia virus treated, tumor bearing mice in several tumor models. Time course
studies revealed that reliable differentiation between tumor bearing and healthy mice can be done as early as 9
days post injection of the virus. Regarding the sensitivity of the newly developed assay system, we could show
that a single infected tumor cell could be reliably detected in this assay.
Conclusion: GusA therefore has the potential to be used as a general marker in the preclinical and clinical
evaluation of (novel) biological therapies as well as being useful for the detection of rare cells such as circulating
tumor cells.
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Background
The regained interest in oncolytic viruses over the past
several years led to an enormous leap in the field with
more and more oncolytic viruses to be described and
yet to come. Not only were those viruses genetically
altered to attenuate their virulence, to improve their
safety profile and enhance their tumor specificity, but
they also were equipped with additional genes for e.g.
cytotoxins, cytokines, prodrug converting enzymes and
reporter genes that improved the overall performance of
these viruses [1,2]. Among those, vaccinia virus is one of
the most promising candidates and has several advan-
tages: Since this large DNA virus encodes e.g. its own
DNA polymerase it is able to replicate in the cytoplasm
of infected host cells thereby minimizing the risk of
DNA integration into the host genome. Moreover, vac-
cinia virus displays a broad host cell range, rapid spread
and a high capacity (up to 25 kbp) for genetic payload
of foreign DNA [3]. Of note and importance regarding
the safety of vaccinia virus, is also its billion-fold use in
humans during the eradication program of smallpox, as
well as the fact that vaccinia virus is not a human
pathogen. On top of that, recombinant vaccinia virus
strains (rVACVs) specifically colonize solid tumors in
mice while not infecting other organs [4-7]. Therefore,
its use in human patients was pursued and first human
trials have already been carried out successfully [8-11].
A reliable monitoring of successful tumor colonization
in humans would have an enormous impact not only on
clinical trials, but also to predict possible outcomes of
oncolytic virus therapy. In this aspect, we and others
used different kind of reporter genes for optical (e.g.
[5]), or radiological (e.g. [12-15]) imaging modalities.
This enabled visualization of virus replication within live
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animal models. However, as optical imaging has strong
limitations in penetration depth and radiological ima-
ging is time consuming and requires the need of specia-
lized personnel and expensive equipment, a cheap and
simple method with short turn-around-times is urgently
needed. In particular, if this method could also be used
in other biological therapy approaches.
Beta-glucuronidases catalyze the hydrolysis of ß-D-
glucuronides into the corresponding D-glucuronate and
alcohol. While the mammalian enzymes with a pH-opti-
mum under acidic conditions (pH 4 to 5) have strongly
reduced capacity at normal (neutral) tissue pH, the E.
coli enzyme encoded by gusA works optimal in the
range of pH 6.8 to 7.7 [16].
Its first use as a (fusion-)reporter gene was described by
Jefferson et al. [17,18] and was extensively used in plant
physiology studies. In mammals, bacterial glucuronidase
was mainly used in prodrug studies, due to the very low
abundance of human glucuronidase in human serum [19].
Several strategies were successfully employed: e.g. fusion
of cancer specific antibody-fragments with beta-glucuroni-
dase [20] or tumor selective expression of the enzyme
using bacteria [21] or adenoviruses [22,23]. The reporter
gene properties of the enzyme were not studied as exten-
sively in animals. However, two independent approaches
were published that looked at the potential of using beta-
glucuronidase as a target structure for radiotracers in posi-
tron-emission-tomography [24,25]. In another study, a
membrane-anchored form of a mouse-glucuronidase was
used in combination with the fluorescein di-beta-D-glu-
curonide (FDGlcU) which was hydrolyzed to a fluorescent
reporter that could be used to assess the location and per-
sistence of gene expression in vivo [26].
Here, we show that beta-glucuronidase in combination
with fluorogenic substrates cannot only be used for
localization of enzyme expression, but also as a general
biomarker for foreign protein expression in serum sam-
ples. Consequently, the described test-system could be
applied to all kinds of biological therapies which depend
on heterologous gene expression.
Materials and methods
For evaluation of the described glucuronidase assay it was
necessary to confirm the heterologous gene expression of
the described vaccinia virus strain by Western blot analysis
as well as immuno-staining studies in cell culture and
infected tumor sections. The assay itself (described in the
“Fluorogenic probes and detection of fluorescence pro-
ducts” section) was tested with purified enzyme as well as
with samples from vaccinia virus injected animals.
Cell culture
Human A549 lung cancer cells (ATCC No. CCL-185)
were cultured in RPMI-1640 medium containing 10%
fetal bovine serum (FBS) and 1% antibiotic-antimycotic
solution (PAA Laboratories, Cölbe, Germany) under
standard cell culture conditions (37°C, 5% CO2).
MTH52c is derived from a malignant small-cell canine
carcinoma of the mammary gland [27] and cultured in
DMEM supplemented with antibiotic-antimycotic solu-
tion and 20% FBS.
Vaccinia viruses
The attenuated vaccinia virus strain GLV-1h68 was pur-
ified as previously described [4]. For generation of con-
trol viruses, lacZ and gusA of GLV-1h68 were replaced
by nonrelevant gene constructs to create viruses nega-
tive for beta-galactosidase (rVACV-LacZ-) and beta-glu-
curonidase (rVACV-GusA-) respectively (Additional File
1, Figure S1).
Infection of cell cultures
Two days before infection, cells were seeded in 6-well
plates for western blot analysis or 12-well plates con-
taining sterile cover slips for microscopy studies. 90%
confluent cell layers were either mock treated or
infected with GLV-1h68, rVACV-LacZ- or rVACV-
GusA- at a multiplicity of infection (MOI) of 0.1 for 1 h
at 37°C and 5% CO2 in medium containing 2% FBS.
Afterwards the infection medium was aspirated and
replaced by standard cell culture medium.
Western blot analysis
For detection of proteins, infected cells were harvested
and lysed in SDS sample buffer at 6, 12, 24 and 48
hours post-infection (hpi). Lysates were separated by
10% SDS-Polyacrylamide gel electrophoresis and subse-
quently transferred onto a nitrocellulose membrane
(Whatman GmbH, Dassel, Germany). After blocking in
5% skim milk in PBS, the membrane was incubated with
anti-beta-glucuronidase rabbit polyclonal antibody
(G5420, Sigma-Aldrich, Schnelldorf, Germany), anti-
beta-galactosidase rabbit polyclonal antibody (A-11132,
Molecular Probes, Leiden, Netherlands), anti-GFP rabbit
polyclonal antibody (sc-8334, Santa Cruz, Heidelberg,
Germany) or anti-beta-actin mouse monoclonal anti-
body (ab6276, Abcam, Cambridge, UK). The first anti-
bodies were detected using horseradish peroxidase-
conjugated anti-mouse (ab6728, Abcam, Cambridge,
UK) or anti-rabbit (ab6721, Abcam, Cambridge, UK)
secondary antibodies, followed by enhanced chemilumi-
nescence detection.
X-Gal/X-GlcU staining and microscopy studies
For the analysis of expression and activity of beta-galac-
tosidase and beta-glucuronidase respectively, A549 cells
were seeded on coverslips and infected with 200 PFU
GLV-1h68, rVACV-LacZ- or rVACV-GusA- per well.
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After incubation for 2 days, cells were fixed using 4%
paraformaldehyde and washed twice in PBS. Staining
solutions consisted of 40 μl X-Gal (5-bromo-4-chloro-3-
indolyl-b-D-galactoside, Invitrogen, Karlsruhe, Germany)
and X-GlcU (5-bromo-4-chloro-3-indolyl-b-D-glucuro-
nide, Invitrogen, Karlsruhe, Germany) respectively in
dimethylformamide (40 mg ml-1), ferricyanide (12 mM
K3Fe(CN)6), 5.2 mM MgCl2 and ferrocyanide solution
(12 mM K4Fe(CN)6). Coverslips were stained with either
X-Gal or X-GlcU solution and incubated for 24 h at 37°
C before mounting in Mowiol. Images were taken with
a Zeiss Axiovert 200 M microscope.
Histology and immunofluorescence
For histological analysis, snap-frozen tumors were fixed
in 4% paraformaldehyde/PBS overnight at 4°C. Samples
were embedded in 5% (w/v) low-melt agarose (Appli-
Chem, Darmstadt, Germany) und 100 μm sections were
cut using a Leica VT1000S Vibratome (Leica, Heer-
brugg, Switzerland) as described before [28]. After per-
meabilizing in 0.3% Triton X-100/PBS, sections were
incubated with Hoechst 33342, anti-beta-glucuronidase
rabbit polyclonal antibody (G5420, Sigma-Aldrich,
Schnelldorf, Germany) and anti-beta-galactosidase
chicken polyclonal antibody (ab9361, Abcam, Cam-
bridge, UK) before staining with Cy-5-conjugated donky
anti-rabbit and Cy-3 conjugated donky anti-chicken sec-
ondary antibodies (Jackson ImmunoResearch, West
Grove, PA). Mowiol-embedded sections were examined
using a Leica MZ 16 FA Stereo-Fluorescence Micro-
scope equipped with a Leica DC500 Digital Camera.
Digital Images were processed with Photoshop 7.0
(Adobe Systems, San Jose, CA) and merged to yield
pseudocolored pictures.
Animal studies
A549 and MTH52c xenograft tumors were developed in
6- to 8-week-old nude mice (NCI:Hsd:Athymic Nude
Foxn1nu, Harlan Borchem, Germany) by implanting 5 ×
106 cells subcutaneously in the right abdominal flank.
Two to three weeks after implantation, mice were
anesthetized with isoflurane and injected with a viral
dose of 5 × 106 PFU GLV-1h68, rVACV-LacZ- or
rVACV-GusA- in 100 μl PBS via the retro-orbital sinus
vein.
Blood and urine collection of mice was carried out
under anesthesia by a heparinised capillary pipet (No.
554/20, Assistent, Sondheim, Germany) via the retro-
orbital sinus vein for blood and a bladder catheter (No.
381312, Becton Dickinson, Heidelberg, Germany) for
urine respectively.
All animal experiments were carried out in accordance
with protocols approved by the Regierung von Unter-
franken (Würzburg, Germany) (protocol number AZ
55.2-2531.01-17/08) and/or the the Institutional Animal
Care and Use Committee (IACUC) of Explora BIO-
LABS, located in San Diego Science Center (San Diego,
USA) (protocol number: EB08-003).
Fluorogenic probes and detection of fluorescence
products
The lyophilized fluorogenic probes FDGlcU, FDG and 4-
Methylumbelliferyl-b-D-glucuronide (4-MUG) (Invitro-
gen, Karlsruhe, Germany) were dissolved in DMSO
(36.5 mM). For in-vivo studies, 5 μl of each stock dilu-
tion was mixed with 195 μl PBS and injected intraperi-
toneally. Whole body and urine fluorescence analysis
was performed using a Maestro EX imaging system
(CRI, Woburn, MA). For serum analysis, the collected
mouse serum was diluted 1:15 with PBS and 80 μl of
each sample were mixed with of either 2.5 μg FDGlcU
or 1.5 μg 4-MUG if not otherwise indicated. Human
serum of healthy individuals (Zen-Bio Inc, Research Tri-
angle, NC) was obtained from whole blood and 10 μl
were used in the described assay. After incubation for 1
h at 37°C (if not otherwise indicated), fluorescence was
read in Lumox 384-well plates (Sarstedt, Nümbrecht,
Germany) using an Infinite 200 Pro Microplate Reader
(Tecan, Crailsheim, Germany) or a Spectra Max M5
(Molecular Devices, Sunnyvale, USA) and fluorescence
intensities are listed as relative fluorescence units.
Results
Biological therapies, like e.g. oncolytic virotherapy, are
dependend on the expression of genes that are not func-
tionally expressed in the respective patient. We recently
described the use the rVACV strain GLV-1h68 in com-
bination with a prodrug seco-analog of duocarmycin SA
which is activated by the virus encoded beta-galactosi-
dase [29]. Although very promising results were
observed in cell culture, the synergistic effect in tumor
bearing mice were less pronounced, which was also true
for a bacterial glucuronidase activatable version of the
prodrug (Hess et al, unpublished). Among other poten-
tial reasons for this observation was a non-favorable
pharmacokinetic of the prodrugs. Therefore, we wanted
to analyze the activation and pharmacokinetics of other
beta-galactosidase or glucuronidase substrates that could
actually be visualized by optical imaging.
As fluorescent probes can be directly detected in small
animals, the compounds FDG (substrate for the beta-
galactosidase LacZ) as well as FDGlcU (a glucuronidase
substrate) were injected in tumor bearing mice that had
previously been injected with oncolytic rVACV (GLV-
1h68) encoding both enzymes. Upon cleavage the
probes were converted to fluorescein which resulted in
a change of their fluorescent properties that was readily
detectable with a small animal fluorescence imaging
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system (Figure 1A). Animals that were previously
injected with PBS or the control rVACV strains not
expressing beta-galatosicase (rVACV-LacZ-) and glucur-
onidase (rVACV-GusA-) respectively served as controls.
It became evident that each fluorogenic probe could
indeed be activated in the tumor and that this activation
is dependent on the expression of LacZ and GusA
respectively (Figure 1A and 1C). The maximum fluores-
cein fluorescence in the tumor was observed 120 min
after intraperitoneal injection (Figure 1B). Upon intrave-
nous FDGlcU-injection the maximum fluorescence was
already observed 20 min post injection (Additional File
Figure 1 Fluorogenic compound activation in rVACV-colonized tumors. A) Two hours post intraperitoneal injection of FDG and FDGlcU
tumor specific fluorescein dependent fluorescence was observed in the presence of LacZ- and GusA-expressing vaccinia virus GLV-1h68
respectively. In rVACV-LacZ-negative and rVACV-GusA-negative colonized tumors, only GFP fluorescence was observed (no difference in
fluorescence between pre- and 120 min post fluorogenic compound injection). B) Fluorescence immunohistochemical analysis of GLV-1h68,
rVACV-GusA-negative and rVACV-LacZ-negative colonized tumors. Blue - Hoechst 33342 stained DNA, green - virus encoded GFP, yellow - beta-
galactosidase, red - beta-glucuronidase. C) Tumor specific fluorescence over time post FDGlcU-injection (n = 4; average plus standard deviation is
shown).
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2, Fig. S2). About 6 hours post injection (hpi), the GFP-
dependent fluorescence remained while most of the
compound specific fluorescence was gone (Figure 1A
and 1B).
Consequently it was investigated how the produced
fluorescein was removed from the tumor. Possible
explanations could be fluorescein instability in or com-
pound excretion from the tumor.
In favour of (renal) excretion was the presence of
fluorescein in the urine of injected mice. Moreover,
when fluorescein itself was injected directly into the
tumor the compound accumulated in the bladder and
was then secreted with the urine (data not shown) while
it disappeared from the tumor.
The presence of the activated probe in the urine of
GLV-1h68 injected tumor bearing mice offered the pos-
sibility to evaluate this as a possible biomarker for suc-
cessful tumor colonization. To test this, mice were
anesthesized and urine was isolated via a bladder cathe-
ther before and 90 minutes after i.p. injection of
FDGlcU. Indeed, fluorescein was present in urine of
GLV-1h68 treated tumor bearing animals but could not
be observed in FDGlcU injected control mice that either
had non-colonized or rVACV-GusA- colonized tumors
(Figure 2A, B). Therefore, one could establish a test for
the presence of GLV-1h68 in tumors of live mice with a
simple urine test after systemic injection of FDGlcU.
Nevertheless, we did not proceed to establish a urine
based test system as the injection of FDGlcU in human
patients seemed unlikely.
Although fluorescein obviously was renally excreted, it
was also investigated whether active enzymes that were
specifically produced in the tumor tissue leaked out and
were then present in the serum of GLV-1h68 injected
tumor bearing mice leading to additional (non-tumor
specific) cleavage of FDGlcU. To investigate this, the
serum of tumor bearing mice which were previously
injected with the GusA encoding strain GLV-1h68 was
incubated with FDGlcU or 4-MUG. Both substances can
be hydrolysed by glucuronidase to the fluorescent pro-
ducts fluorescein and 4-MU respectively. As latter has
excitation and emission maxima of 365 nm and 455 nm
respectively, it was not suitable for optical in vivo ima-
ging and therefore only used in in vitro studies. In our
experiments, no fluorescence was observed when mice
were injected with PBS or GusA-negative control
rVACV while the fluorescent compounds clearly were
detectable after co-incubation with serum derived from
GLV-1h68 injected mice (Figure 3A). The serum there-
fore contained active (non-secreted, but shed) enzymes
that were produced in the tumor tissue.
Theoretically, this does pave the way to a simple blood
test that could be used to distinguish tumor bearing
from healthy patients and/or to distinguish between suc-
cessful from unsuccessful tumor colonization of GusA-
encoding oncolytic virus strains in cancer bearing
patients. To confirm this, we retrospectively tested
serum samples (n = 99) from different tumor xenograft
models (GI-101A, A549, DU-145, PANC-1, HT-29) that
were collected in our lab over about 4 years from mice
injected with PBS (n = 33) or treated for different peri-
ods of time (7 to 53 days) with several GusA-positive (n
= 53) or -negative (n = 13) rVACV (Figure 3B). The test
of these probes confirmed a significant (p < 0.001) dif-
ference between the GusA containing group and those
that did not result in GusA-production. As the test was
done in retrospect, we could not confirm/exclude suc-
cessful tumor colonization in those mice which had
Figure 2 Analysis of urine samples derived from mice before, 30 min and 90 min post FDGlcU injection respectively. A) Five μl urine
were analyzed in the Maestro Imaging system. Unmixed fluorescein specific fluorescence is shown. B) Three and seven days post rVACV
injection urine was sampled before and 90 min post FDGlcU injection. Average plus standard deviation of fluorescein specific fluorescence of
GusA-positive (n = 6 for 3 dpi and n = 8 for 7 dpi) and GusA-negative (n = 4) rVACV colonized tumors. * indicates p < 0.05.
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Figure 3 Glucuronidase specific fluorigenic compound activation in serum of tumor bearing mice. A) Tumor bearing mice were mock
injected (n = 2) or injected with GLV-1h68 (n = 6) and rVACV-GusA-negative (n = 6) respectively. Seven days later 5 μl serum was co-incubated
for 1 h at 37°C with 4-MUG and FDGlcU respectively and subsequently specific fluorescence was determined. B) Retrospective serum analysis.
Serum samples (n = 99) from different tumor xenograft models (GI-101A, A549, DU-145, PANC-1, HT-29) were retrospectively tested. Samples
were derived from mock (n = 33) injected mice or mice treated for different periods of time (7 to 53 days) with several GusA-positive (n = 53)
or -negative (n = 13) rVACV. * indicates p < 0.03; *** indicates p < 0.001.
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GusA-negative results in the blood test. This could
explain the negative results for 5 of the GusA-rVACV
injected tumor bearing mice.
Next, it was investigated whether one could confi-
dently decide via the blood test if a tumor was colo-
nized or not. Tumor bearing mice (n = 5) were
systemically injected with a low dose (1 × 105 PFU) of
GLV-1h68. This dose was known to result in coloniza-
tion of only some tumors while other tumors do not
get colonized at all. Serum was then isolated 1, 3, 7, 10
and 14 days later, before mice were sacrificed and
tumor colonization was tested by conventional plaque
assay confirming the results observed by the FDGlcU/
4-MUG based blood test (Figure 4A). The very same 2
out of 5 mice were found to have GLV-1h68 in their
tumors as well as being positive in the FDGlcU/4-
MUG based blood tests.
In another experiment we tested the suitability of the
blood test to differentiate between tumor bearing and
control tumor free mice. Unexpectedly, seven days post
injection of GLV-1h68 in non-tumor bearing mice low
but significant glucuronidase activity was detected in the
serum of tumor free mice. Closer examination of those
mice revealed GFP expression in the paws of 2 mice
(data not shown). Therefore, the mice were sacrificed
and a plaque assay of several organs was used to find
the origin of glucuronidase production (Table 1). Apart
from the two infected paws virus was reproducibly iso-
lated in low concentration from ovaries of non-tumor
bearing mice. Interestingly, ovaries of tumor bearing
mice were essentially free of virus.
Background expression of glucuronidase in healthy
subjects would of course exclude using this test system
for detection of tumors if no difference existed that
allowed differentiation between cancer patients and
healthy individuals. Time course studies in male (n = 12
tumor bearing and 12 tumor free) and female mice (n =
24 tumor bearing and 6 tumor free) over a period of 14-
16 days in which blood was taken every other day (in
one half of the mice blood was taken on even, in the
other on uneven days post virus injection), again showed
low levels of glucuronidase present in the serum of
tumor free mice. These were similar to those observed
in tumor bearing mice until 8 days post virus injection
(Figure 4B and Additional File 3, Fig. S3). After that
however, significant changes occurred. While the glu-
curonidase activity in the serum of tumor free mice
decreased, the fluorescence signal in the tumor bearing
animal probes increased.
Taken together, 9 days after injection of the virus it
was possible to decide with confidence whether A) an
existing tumor was successfully colonized and/or B) a
tumor was present in the gusA encoding rVACV
injected mouse.
In a next step the sensitivity and performance of the
described test was evaluated in in vitro studies regarding
its clinical translatability. We found a positive correla-
tion between the fluorescence signal intensities and
increasing A) glucuronidase concentration, B) substrate
(FDGlcU or 4-MUG) concentration and C) incubation
time (Additional File 4, Fig. S4). The data also revealed
that very low glucuronidase concentrations could be
detected using the fluorogenic FDGlcU or 4-MUG sub-
strates which should allow detection of lysed tumor cells
not only in mice but also in humans. Feasibility in the
presence of human serum was shown by running the
assay in the presence or absence of 10 μl human serum
(Additional File 5, Fig. S5). The data revealed that
neither the sensitivity nor the fluorescence intensity of
the assay was changed in the presence of human serum.
As the presence of glucuronidase relies on the produc-
tion by infected cancer cells, the minimal amount of
infected cancer cells was tested that was needed to gen-
erate a positive fluorescent signal. For this, A549 cells
were infected with GLV-1h68 or control-rVACV. One
day later, the amount of infected cells was determined
by counting and flow cytometry and the cells were
diluted and seeded in half-log dilutions in 384-well
plates with concentrations varying from approx. 1.0 to
1000 infected cells/well and co-incubated with 6.3 μg
FDGlcU and 3.4 μg 4-MUG respectively. To obtain high
sensitivity, the probes were incubated at 37°C over night
and analyzed the next day (Figure 5). Surprisingly, even
a single infected cancer cell could be readily detected
using this test when using 4-MUG as a substrate. This
allowed us to calculate the potential sensitivity of the
described test for the detection of tumors in human
patients using two different approaches: 1) Assuming
that more serum (e.g. 50 μl) would be used when testing
the system on human patient samples, and an average
total blood volume of about 4.7 liters, only approx. 105
infected cancer cells would be sufficient to generate a
detectable fluorescent signal. 2) The fluorescent signal
generated from a single cancer cell was similar to that
obtained from 0.2 units glucuronidase. Increasing the
sensitivity by adding more fluorescent substrate 0.05
units glucuronidase were easily detectable, correspond-
ing to a concentration of 1 unit glucuronidase/ml serum
(again using 50 μl serum/test) or 4700 units/average
blood volume of a human patient. Therefore, as low as
2.4 × 104 infected cancer cells would be sufficient for a
positive signal.
Discussion
Biological therapies including stem cell therapy, gene
therapy, immunotherapy, oncolytic virotherapy etc. are
gaining more and more impact in e.g. regenerative med-
icine, immunology, oncology and treating various
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Figure 4 Signal generation is both dependent on presence of tumors and gusA-encoding rVACV. A) Confirmation of successful tumor
colonization after low-dose injection of 1 × 105 pfu GLV-1h68. In the left panel time dependent 4-MU fluorescence is shown for individual sera
of rVACV injected tumor bearing mice. The sera of two mice (#482 and #486) resulted in generation of significant amounts of 4-MU. Viral titer
analysis of tumors from the same mice revealed that only those mice (#482 and #486) had virus colonized tumors which also resulted in
generation of 4-MU. B) Tumor bearing (black) and non-tumor bearing (grey) control male (left panel) and female (right panel) mice were
injected with 5 × 106 pfu GLV-1h68 into the retro-orbital sinus vein. Analysis of sera revealed conversion of the fluorigenic compounds FDGlcU
(solid lines) and 4-MUG (broken lines) in all mice. Significant differences (p < 0.05) between tumor bearing and control mice was observed after
9 dpi. Results show average plus standard deviation of fluorescein and 4-MU fluorescence.
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diseases. All of these require the expression of certain
genes that usually are not or only weakly expressed in
the targeted tissue. While progress in terms of biological
effectiveness is made in each field, no common reporter
system exists which is cost-efficient, easy to use in clini-
cal laboratories and at the same time allows short turn-
around-times.
In our studies we used oncolytic rVACV strains as a
model to investigate the potential of a (bacterial) beta-glu-
curonidase in combination with fluorogenic probes to be
used as a general reporter system in biological therapies.
The bacterial glucuronidase was chosen as reporter gene,
since the pH in blood (pH of about 7.4) is in the pH-opti-
mum range (pH 6.8 - 7.7) of the bacterial enzyme [16]
while mammalian beta-glucuronidases are most active at
pH 4 to 5 and present almost exclusively in lysosomes.
Moreover, the bacterial enzyme displays much higher spe-
cific activity compared to the human beta-glucuronidase
[30]. On the other hand, bacterial enzymes usually have
much higher immunogenicity than their mammalian
counterparts and thus might be hindered in their efficacy
[31]. Consequently, the group of S. Roffler selected
mutants of human beta-glucuronidase with enhanced
activity at neutral pH [30] and fused this protein to single
chain humanized antibodies for enhanced antibody-direc-
ted enzyme prodrug therapy [32]. Therefore, it should also
be possible to use this optimized human beta-glucuroni-
dase in the detection system described herein.
Furthermore, the possibility to direct active beta-glu-
curonidase into the cytoplasm (this study and many
others, e.g. [17]), attach it to the cell surface (e.g.
[23,33]), or secrete from producing cells (e.g. [32,34])
offers a number of different potential applications.
Cytoplasm associated beta-glucuronidase seems to be
a very attractive marker for oncolytic viruses. Not only
does presence of glucuronidase in the serum show suc-
cessful tumor colonization, but also indicates a
therapeutic effect: Active enzyme can only get in the
serum when (tumor) cells are lysed. Future studies will
show if responding and non-responding tumors can be
differentiated using the described test system.
The detection of cell surface associated beta-glucuro-
nidase could be helpful in studies relying on transfection
of cells or following bacteria or parasite infections in
which blood-borne pathogens express a membrane- or
cell-wall-anchored glucuronidase. Also, the previously
mentioned (non-membrane passing) prodrug therapies
would benefit from detection of beta-glucuronidase in
the blood: The enzyme would only be observed upon
Table 1 Viral distribution in tumor bearing and non-tumor bearing mice 14 dpi
pfu/g tissue fluorescence
mouse # tumor blood ovaries spleen kidneys liver lung brain paw 4-MU fluorescein
1 NA ND ND ND ND ND ND ND 2.10E+06 8599 1179
2 NA ND 2500 ND ND ND ND 100 ND 4418 607
3 NA ND 5300 ND ND ND ND 20 ND 6775 855
4 NA ND 12000 ND 100 ND ND ND 5.00E+05 14587 2641
5 NA ND 8800 ND ND 100 ND ND ND 4325 483
6 NA ND ND ND ND 0 ND ND ND 5272 667
7 2.70E+07 ND ND 40 ND ND 20 ND ND 40812 168977
8 5.15E+07 ND ND 100 ND ND ND ND ND 43732 61137
9 2.65E+07 ND ND ND 100 ND ND ND ND 43866 43572
10 9.00E+06 ND 20 20 100 ND 80 ND ND 38449 135454
11 8.50E+06 ND ND ND 20 ND ND ND ND 41645 28754
NA - not applicable. ND - not detectable. Detection limit 20 pfu/g.
Figure 5 Minimal amount of GLV-1h68 infected cancer cells
necessary for positive detection. A549 cells were infected with
GLV-1h68 or control-rVACV (rVACV-GusAneg). One day later, the
amount of infected cells was determined by flow cytometry and
the cells were seeded in half-log dilutions in 384-well plates with
concentrations varying from 1.0 to 1000 cells/well and co-incubated
with FDGlcU and 4-MUG respectively. Data represent average plus
standard deviation (n = 6).
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successful prodrug treatment as only then, the active
enzyme is released from the tumor.
Secreted beta-glucuronidase could be used as a simple
marker for cell survival. Genetically altered cells should
secrete active enzyme as long as they are viable. Again,
a small number of cells would be sufficient for detection
and the amount of beta-glucuronidase in the blood
should be correlating with the amount of cells produ-
cing the enzyme. Therefore, it will be possible to moni-
tor e.g. stem cell therapies, tissue regeneration etc.
In each case one will have to decide whether the
achieved enzyme concentration is sufficient to be detected
in the respective assays. Here, we calculated that theoreti-
cally only 2.4 × 104 vaccinia virus infected cancer cells
might be enough to be detected in humans. With a dia-
meter of 50 μm/cell this would correspond to a volume of
only 1.6 mm3. Of course, it can be argued that in patients
this number might be higher, as e.g. not all virus infected
cells will release all of their enzymes into the blood stream
upon lysis. But even if the number of infected cells is 10 or
even 100-fold higher, the tumor diameter would only be
3.1 and 6.7 mm, respectively. Nevertheless, only clinical
trials such as those in which GLV-1h68 is currently evalu-
ated for safety in human cancer patients [11], will deter-
mine whether the proposed detection system can be
translated to a clinical setting.
Presumably, similar evaluations will be necessary when
applying the presented beta-glucuronidase test in other
applications such as in infectious disease studies, stem
cell research/therapy etc. both in basic as well as in
translational research.
Conclusions
Taken together, we demonstrated that glucuronidase (in
our case encoded by rVACV) in combination with fluoro-
genic probes has the potential to be used as a general repor-
ter system for heterologous gene expression in biological
therapies. Our results provide evidence that the described
system cannot only be used for imaging of tumors in the
body, but also to confirm viral colonization of these tumors
or even the diagnosis of tumors in screening studies.
Additional material
Additional file 1: Figure S1. Viral strains used in this manuscript. A)
Schematic virus constructs. The viral F14.5L, thymidine kinase and
hemagluttinin encoding genes of the wild type Lister strain were
replaced by the indicated marker genes. B) Verification of marker gene
expression by Western blot analysis at 6, 12, 24 and 48 hours post A549
cell infection respectively (multiplicity of infection 0.5). Beta-actin served
as loading control. C) X-Gal and X-Gluc staining of single viral plaques.
GLV-1h68 encodes both beta-galactosidase and beta-glucuronidase,
while control strains lack one or the other gene.
Additional file 2: Figure S2. Time dependent conversion of FDGlcU
in the same mouse injected with GLV-1h68. A A549 tumor-bearing
mouse was injected with GLV-1h68 10 days before FDGlcU injection was
performed. Intraperitoneal (i.p.) injection (lower row pictures) occurred 24
hours before intravenous (i.v.) injection (upper row pictures). This allowed
the fluorescence signal to decline completely before getting the kinetics
in the very same mouse.
Additional file 3: Figure S3. Individual mouse data from Figure 4B.
Tumor bearing (red) and non-tumor bearing (grey) control male (upper
panels) and female (lower panels) mice were injected with 5 × 106 pfu
GLV-1h68. Analysis of sera revealed conversion of the fluorigenic
compounds FDGlcU (left panels) and 4-MUG (right) in all mice.
Additional file 4: Figure S4. Positive correlation between the
fluorescence signal intensities and increasing glucuronidase
concentration, fluorogenic substrate concentration (left panels, 4-MUG in
A, FDGlcU in B) and incubation time (right panels).
Additional file 5: Figure S5. Glucuronidase assay results
independent from presence of human serum. Increasing amounts of
E. coli glucuronidase were co-incubated with 4-MUG (upper panel) or
FDGlcU (lower panel) in the presence or absence of human serum.
Serum samples from 3 different healthy individuals were tested in
parallel. Cover art. The cover shows the generation of fluorescent
products from fluorigenic probes upon cleavage by beta-glucuronidase.
From bottom to top decreasing concentrations of beta-glucuronidase
were co-incubated with 4-Methylumbelliferyl-b-D-glucuronide,
Fluorescein-di-beta-D-glucuronide or without fluorigenic probe in a 384-
well plate. The blue compound 4-Methylumbelliferyl and the green
Fluorescein were excited using UV-light and photographed without the
use of additional emission filters. The very sensitive assay is able to
detect picogram amounts of beta-glucuronidase - sufficient for detection
of a single beta-glucuronidase expressing cell - as described by Hess et
al. in this issue.
List of abbreviations
FBS: fetal bovine serum; FDG: Fluorescein di-β-D-galactopyranoside; FDGlcU
-fluorescein di-β-D-glucuronide; GFP: Green fluorescent protein; GusA:
bacterial glucuronidase; hpi: hours post-infection; LacZ: bacterial beta-
galactosidase; MOI: multiplicity of infection; 4-MUG: 4-Methylumbelliferyl-b-D-
glucuronide; PFU: plaque forming units; rVACV: recombinant vaccinia virus
strain; X-Gal: 5-bromo-4-chloro-3-indolyl-β-D-galactoside; X-GlcU 5-bromo-4-
chloro-3-indolyl-β-D-glucuronide.
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